infectious disease Archives -

An FDA advisory committee has recommended approval of Cidara Therapeutics’ once-weekly antifungal therapy rezafungin, setting it up to

FDA advisors back Cidara antifungal rezafungin

https://pharmaphorum.com/news/fda-advisors-back-cidara-antifungal-rezafungin/

News/ News/ Sales and Marketing

Sandoz bulks up with Mycamine ahead of spin-off

Phil Taylor antifungal, Astellas, infectious disease, Novartis, Sales and Marketing, Sandoz 0 Comment

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with

Sandoz bulks up with Mycamine ahead of spin-off

https://pharmaphorum.com/news/sandoz-bulks-up-with-mycamine-ahead-of-spin-off/

News/ News/ R&D

With filing due soon, Moderna stakes a claim to the RSV vaccine market

Phil Taylor GSK, infectious disease, Moderna, Pfizer, respiratory syncytial virus, vaccine 0 Comment

Look out, Pfizer and GSK. Moderna is looking to make a swift dash to the finish line with

With filing due soon, Moderna stakes a claim to the RSV vaccine market

https://pharmaphorum.com/news/with-filing-due-soon-moderna-stakes-a-claim-to-the-rsv-vaccine-market/

Market Access/ News/ News

FDA starts review of Sanofi, AZ antibody for RSV prevention

Phil Taylor AstraZeneca, infectious disease, nirsevimab, respiratory syncytial virus, Sanofi 0 Comment

The clock has started ticking on the FDA’s review of Sanofi and AstraZeneca’s one-shot antibody to protect newborns

FDA starts review of Sanofi, AZ antibody for RSV prevention

https://pharmaphorum.com/news/fda-starts-review-of-sanofi-az-antibody-for-rsv-prevention/

News/ News/ R&D

mRNA can deliver universal flu vaccine, say US researchers

Phil Taylor infectious disease, influenza, mRNA, mRNA vaccines, vaccines 0 Comment

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of

mRNA can deliver universal flu vaccine, say US researchers

https://pharmaphorum.com/news/mrna-can-deliver-universal-flu-vaccine-say-us-researchers/

News/ News/ Novartis/ R&D/ Top pharmaceutical companies

Novartis, MMV take new malaria drug combination into phase 3

Phil Taylor Coartem, ganaplacide, infectious disease, Malaria, Novartis, parasitology 0 Comment

Novartis and the non-profit Medicines for Malaria Venture (MMV) have advanced a novel drug combination for malaria into

Novartis, MMV take new malaria drug combination into phase 3

https://pharmaphorum.com/news/novartis-mmv-take-new-malaria-drug-combination-into-phase-3/

News/ News/ R&D

As resistant tuberculosis rises, GSK says trial backs novel antibiotic

Phil Taylor antibiotic, antimicrobial resistance, GlaxoSmithKline, infectious disease, tuberculosis 0 Comment

With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a

As resistant tuberculosis rises, GSK says trial backs novel antibiotic

https://pharmaphorum.com/news/gsk-says-trial-data-backs-novel-drug-for-resistant-tuberculosis/

News/ News/ R&D

GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop

Phil Taylor antisense oligonucleotides, bepirovirsen, GlaxoSmithKline, hepatitis B, infectious disease, Ionis Pharmaceuticals 0 Comment

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus

GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop

https://pharmaphorum.com/news/gsk-plans-phase-3-for-hepatitis-b-drug-bepirovirsen-despite-efficacy-drop/

Market Access/ News/ News/ News/ R&D

GSK preps filing for novel antibiotic for urinary tract infections

Phil Taylor antibiotic, antimicrobial resistance, gepotidacin, GlaxoSmithKline, infectious disease 0 Comment

In an encouraging development for the fight against antimicrobial resistance (AMR), GSK’s novel antibiotic gepotidacin has shown efficacy

GSK preps filing for novel antibiotic for urinary tract infections

https://pharmaphorum.com/news/gsk-preps-filing-for-novel-antibiotic-for-urinary-tract-infections/

Trending

infectious disease

Login